Registre HEAR, Healthcare European Amyloidosis Registry

Summary

This is a non-interventional, prospective, retrospective, non-comparative, multi-center study. In order not to interfere with patient management, the study is observational. Thus, no follow-up visit is imposed. The data collection will be limited to the data related to the management of the patients included throughout their follow-up. This study is intended for all patients with a confirmed or suspected diagnosis of cardiac amyloidosis. Three cohorts will be identified: the HEAR (Healthcare European Amyloidosis Registry)-Retrospective Cohort, the HEAR(Healthcare European Amyloidosis Registry)-Retrospective-Prospective Cohort and the HEAR (Healthcare European Amyloidosis Registry)-Prospective Cohort.

Eligibility

INCLUSION CRITERIA

1. Patients must meet all of the following inclusion criteria to be included in the study:

   * Major patient
   * Protected adult patient (guardianship or curatorship)
2. Prospective Cohort:

   Patients referred or who have been referred to the participating centre for suspected amyloidosis.

   Patient who signed the patient information "Prospective Cohort" note
3. Retro-prospective Cohort:

   Patient already followed in the center with a confirmed diagnosis of amyloidosis Patient who signed the "retro-prospective cohort" patient information note
4. Retrospective cohort:

Deceased patients followed in the center with a confirmed diagnosis of amyloidosis

Study participants will not be compensated for their participation

EXCLUSION CRITERIA The patient has expressed his/her refusal to participate Participation in another study, even an interventional one, is not a criterion for non-inclusion.

Conditions2

Browse More Trials